These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26019441)

  • 21. Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved.
    Abdelqader A; Kabacam G; Woreta TA; Hamilton JP; Luu H; Al Khalloufi K; Saberi B; Philosophe B; Cameron AM; Gurakar A
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):1-5. PubMed ID: 28260422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver transplantation for viral hepatitis in 2015.
    Ferrarese A; Zanetto A; Gambato M; Bortoluzzi I; Nadal E; Germani G; Senzolo M; Burra P; Russo FP
    World J Gastroenterol; 2016 Jan; 22(4):1570-81. PubMed ID: 26819523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver transplantation from anti-hepatitis C virus-positive donors: our experience.
    Álvaro E; Abradelo M; Fuertes A; Manrique A; Colina F; Alegre C; Calvo J; García M; García-Sesma A; Cambra F; Sanabria R; Moreno E; Jimenez C
    Transplant Proc; 2012; 44(6):1475-8. PubMed ID: 22841188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
    Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
    Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
    Yoshida EM; Kwo P; Agarwal K; Duvoux C; Durand F; Peck-Radosavljevic M; Lilly L; Willems B; Vargas H; Kumar P; Brown RS; Horsmans Y; De-Oertel S; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault N; Rizzetto M; Müllhaupt B
    Ann Hepatol; 2017; 16(3):375-381. PubMed ID: 28425407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.
    Tamè M; Buonfiglioli F; Del Gaudio M; Lisotti A; Cecinato P; Colecchia A; Azzaroli F; D'Errico A; Arena R; Calvanese C; Quarneti C; Ballardini G; Pinna AD; Mazzella G
    World J Gastroenterol; 2013 Aug; 19(32):5278-85. PubMed ID: 23983430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
    Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
    World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals.
    Coilly A; Roche B; Duclos-Vallée JC; Samuel D
    Liver Int; 2015 Jan; 35 Suppl 1():44-50. PubMed ID: 25377540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.
    Tanimine N; Tanaka Y; Abe T; Piao J; Chayama K; Ohdan H
    Transplantation; 2016 Feb; 100(2):355-64. PubMed ID: 26714120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience.
    Ofosu A; Durand CM; Saberi B; Alqahtani S; Ucbilek E; Belden M; Cameron AM; Gurakar A
    Exp Clin Transplant; 2015 Nov; 13 Suppl 3():7-10. PubMed ID: 26640901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in.
    Price JC; Terrault NA
    Liver Transpl; 2015 Apr; 21(4):423-34. PubMed ID: 25604355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of hepatitis C patients with decompensated liver disease.
    Hsu CS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
    Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
    Saab S; Gonzalez YS; Huber C; Wang A; Juday T
    Liver Int; 2016 Apr; 36(4):515-21. PubMed ID: 26610059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.
    Dumortier J; Boillot O; Scoazec JY
    World J Gastroenterol; 2014 Aug; 20(32):11069-79. PubMed ID: 25170196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early and extended therapy for recurrent hepatitis C after liver transplantation.
    García-Pajares F; Almohalla C; Lorenzo Pelayo S; Ruiz Zorrilla R; Pinto P; Ramos C; Sanchez Antolin G; Paton AC
    Transplant Proc; 2012; 44(6):1571-3. PubMed ID: 22841217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of HCV transplant patients with triple therapy.
    Coilly A; Roche B; Duclos-Vallée JC; Samuel D
    Liver Int; 2014 Feb; 34 Suppl 1():46-52. PubMed ID: 24373078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
    Gurusamy KS; Tsochatzis E; Toon CD; Xirouchakis E; Burroughs AK; Davidson BR
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006803. PubMed ID: 24307460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.